PPiper Sandler PPalantir · PLTR

Piper Sandler Reiterates Overweight on Palantir, $230 PT

Aug 4, 2026· Analyst: Clark Jeffries· 1 min read· Reproduced verbatim
Rating
Buy
Price target
$230
Previous
Implied upside
+83%

Piper Sandler analyst Clark Jeffries reiterated an Overweight rating and $230 price target on Palantir (NASDAQ: PLTR).

“U.S. Commercial Reaccelerates to 149% Growth, FY26E Now Calls for 82% Growth; Total revenue growth reached 93% this quarter as U.S. Commercial reaccelerated to 149% y/y growth vs.

133% last quarter, growing $169M sequentially, the highest quarterly increase we have ever seen in any business segment.

Next quarter could present the crossover point, where Commercial exceeds Government for the first time. If not by Q3, then by Q4, with U.S. Commercial revenue now expected to grow 134% in FY26E.

With aggregate FY26E revenue growth being raised to 82% y/y, we think it is worth reflecting on the fact that over the past six months FY26 growth assumptions have risen 21 pts. or $965M (from 61% entering the year to 82% today).

With only $280M of that YTD increase coming from U.S. Commercial, we think Palantir growth is much more diversified than commonly appreciated.

We remain very bullish on Palantir growth prospects across both Government and Commercial and reiterate our Overweight rating and $230 PT.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.